Latest News and Press Releases

1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mgBempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and...

ANN ARBOR, Mich., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing oral therapies for the treatment...

On track to initiate global pivotal Phase 3 studies and CVOT in the fourth quarter Aligned with global regulatory authorities on a consistent definition of statin intolerance Conference...

ANN ARBOR, Mich., May 04, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...

ANN ARBOR, Mich., March 08, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...

ANN ARBOR, Mich., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...

ANN ARBOR, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...

ANN ARBOR, Mich., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...

ANN ARBOR, Mich., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...

ANN ARBOR, Mich., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...